The stock will trade on FDA feedback regarding the sunRIZE congenital HI study, which remains the key binary catalyst. upLIFT tumor HI topline results expected before end of 2026 provide a secondary catalyst. Monitor cash runway — at current burn rate, the company has approximately 18 months of runway.
Price Chart
Executive Summary
Rezolute reported Q4 FY2026 results with a net loss of $20.5M ($-0.20 EPS), missing consensus estimates of $-0.14 by 42.9%. The company highlighted positive interim data from the upLIFT tumor HI study (7 of 8 participants met the primary endpoint) but noted that the Phase 3 sunRIZE congenital HI study data remains under FDA review after failing its primary endpoint. Cash burn continues with $107.8M in cash and investments as of June 30, 2026, down from $167.9M a year ago.
Key Financial Metrics
Key Facts
- Q4 FY2026 net loss of $20.5M vs $24.4M in the year-ago quarter
- EPS of $-0.20 missed consensus of $-0.14 by 42.9%
- Cash and investments at $107.8M as of June 30, 2026, down from $167.9M a year ago
- Full year FY2026 net loss of $77.6M vs $74.4M in FY2025
- upLIFT tumor HI study: 7 of 8 enrolled participants met the primary endpoint
- Phase 3 sunRIZE congenital HI study data remains under FDA review after failing primary endpoint
- R&D expenses decreased to $14.9M in Q4 from $20.9M a year ago
- G&A expenses increased to $6.7M in Q4 from $5.0M a year ago
Financial Impact
EPS miss of 42.9% vs consensus; cash burn of ~$60M over the fiscal year
Risk Factors
- FDA may require a new randomized controlled trial for congenital HI, which would significantly delay or impair the program
- Cash burn of ~$60M/year with no approved products or revenue
- sunRIZE study failed primary endpoint, creating regulatory uncertainty
- Dilution risk if additional capital is needed
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-110412 |
| Document: tm2625842d1_8k.htm | 0001104659-26-110412 |
| Document: 0001104659-26-110412-index-headers.html | 0001104659-26-110412 |
| Document: 0001104659-26-110412-index.html | 0001104659-26-110412 |
| Document: 0001104659-26-110412.txt | 0001104659-26-110412 |
| 8-K Data (Synthetic) | 0001104659-26-110412 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | DEF 14A | $3.86 | awaiting T+20 | — | $4.11 (+6.35%) |
Oct 14, 2026 12d ago | 8-K | $3.90 | awaiting T+20 | — | $4.11 (+5.26%) |
Oct 5, 2026 22d ago | 8-K | $4.33 | awaiting T+20 | — | $4.11 (−5.20%) |
Sep 24, 2026 4w ago | 8-K | $3.90 $3.86 | ▲ +1.15% | ▼ −0.32% | $4.11 (−5.26%) |
Sep 24, 2026 4w ago | Press Release | $3.90 $3.86 | ▲ +1.15% | ▼ −0.32% | $4.11 (−5.26%) |
Jul 21, 2026 14w ago | Press Release | $5.09 $4.66 | ▼ −8.45% | ▼ −11.01% | $4.11 (−19.35%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.86 $5.13 | ▲ +32.90% | ▲ +31.01% | $4.11 (+6.35%) |
Jun 4, 2026 20w ago | Press Release | $4.51 $4.91 | ▲ +8.87% | ▲ +10.24% | $4.11 (−8.98%) |
Jun 2, 2026 21w ago | 8-K | $4.00 $4.95 | ▲ +23.75% | ▲ +25.32% | $4.11 (+2.63%) |
May 12, 2026 23w ago | 8-K | $3.33 $3.86 | ▲ +15.92% | ▲ +16.53% | $4.11 (+23.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers